🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 65 Guangzhou 54 Wuhan 33 Shanghai 28 Nanjing 25
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University451 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University181 Nanfang Hospital, Southern Medical University138 AstraZeneca133 Guangdong Provincial People's Hospital81 Clear sponsor filter
Site location
Beijing65 Guangzhou54 Wuhan33 Shanghai28 Nanjing25
All 65 locations
Target enrolment
to
54 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab
NCT07039422Primary Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia
Novartis Pharmaceuticals
Phase 2
60
Guangzhou, Dalian, Tianjin
2026-06-26
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Novartis Pharmaceuticals
Phase 3
460
Hefei, Guangzhou, Wuhan, Nanjing, Nantong, Changchun, Jinan, Yantai
2026-06-16
Recruiting
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
NCT07468071Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation
Novartis Pharmaceuticals
Phase 1/2
40
Guangzhou, Changsha
2026-06-08
Recruiting
Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa
NCT07489573Hidradenitis Suppurativa (HS)
Novartis Pharmaceuticals
Phase 4
36
Guangzhou, Shijiazhuang, Chengdu, Hangzhou, Ningbo, Wenzhou, Beijing, Shanghai
2026-06-01
Recruiting
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NCT07517263Cardiovascular Disease and Lipoprotein(a)
Novartis Pharmaceuticals
Phase 3
5,700
Beijing, Lanzhou, Foshan, Guangzhou, Harbin, Changsha, Baotou, Nanjing
2026-05-11
Recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
NCT07326709Huntington Disease
Novartis Pharmaceuticals
Phase 3
770
Guangzhou, Wuhan, Changsha, Chengdu, Hangzhou
2026-03-24
Recruiting
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
NCT07431177Non-segmental Vitiligo
Novartis Pharmaceuticals
Phase 2
210
Guangzhou, Wuhan, Beijing, Shanghai
2026-03-09
Recruiting
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
NCT07190300Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Novartis Pharmaceuticals
Phase 1/2
181
Guangzhou
2026-01-13
Recruiting
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504Secondary Progressive Multiple Sclerosis (SPMS)
Novartis Pharmaceuticals
Phase 3
1,275
Guangzhou, Zhengzhou, Wuhan, Hohhot, Suzhou, Changchun, Shenyang, Yinchuan
2025-11-11
Recruiting
Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
NCT07102628Acute Coronary Syndrome
Novartis Pharmaceuticals
Phase 3
300
Beijing, Guangzhou, Luoyang, Xuzhou, Nanchang, Wenzhou, Fuzhou, Jining
2025-10-03
Recruiting
Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease
NCT06824103Graft vs. Host Disease, Chronic Graft vs. Host Disease, Corticosteroid-refractory Chronic Graft vs. Host Disease
Novartis Pharmaceuticals
Phase 4
50
Hefei, Guangzhou, Nanning, Guiyang, Shijiazhuang, Zhengzhou, Wuhan, Nanjing
2025-09-09
Recruiting
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
NCT06855277Prostate Cancer
Novartis Pharmaceuticals
Phase 3
940
Fuzhou, Guangzhou, Wuhan, Nanjing, Shenyang, Chengdu, Hangzhou, Beijing
2025-07-01
Recruiting
A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China
NCT06931691Paroxysmal Nocturnal Hemoglobinuria
Novartis Pharmaceuticals
Observational
80
Hefei, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nantong, Nanchang, Changchun
2025-06-10
Recruiting
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
NCT06711887Lupus Nephritis
Novartis Pharmaceuticals
Phase 3
348
Guangzhou, Shantou, Shenzhen, Liuzhou, Wuhan, Changchun, Shenyang, Binzhou
2025-05-19
Recruiting
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
NCT06947993Atopic Dermatitis
Novartis Pharmaceuticals
Phase 2
224
Guangzhou, Shantou, Changsha, Changchun, Hangzhou, Beijing, Shanghai
2025-05-16
Recruiting
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
NCT06780670Prostate Cancer
Novartis Pharmaceuticals
Phase 2/3
443
Fuzhou, Wuhan, Nanjing, Shenyang, Xian, Chengdu, Beijing, Guangzhou
2025-02-27
Recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
NCT06744920Generalized Myasthenia Gravis
Novartis Pharmaceuticals
Phase 3
180
Hefei, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Wuxi, Changchun, Beijing
2025-02-07
Active, closed
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
NCT06799000Hidradenitis Suppurativa
Novartis Pharmaceuticals
Phase 3
588
Fuzhou, Guangzhou, Wuhan, Changsha, Changchun, Shenyang, Xian, Chengdu
2025-01-31
Active, closed
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
NCT06517758Generalized Myasthenia Gravis
Novartis Pharmaceuticals
Phase 3
146
Hefei, Guangzhou, Shenzhen, Shijiazhuang, Changsha, Suzhou, Xi'an, Xianyang
2024-07-31
Active, closed
Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction
NCT06372925Plaque, Atherosclerotic
Novartis Pharmaceuticals
Phase 4
318
Hefei, Fuzhou, Guangzhou, Shenzhen, Zunyi, Harbin, Zhengzhou, Wuhan
2024-07-09
Active, closed
Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease
NCT06462469Steroid-refractory Acute Graft Versus Host Disease
Novartis Pharmaceuticals
Phase 4
36
Guangzhou, Zhengzhou, Wuhan, Xian, Hangzhou, Beijing, Taian, Tianjin
2024-07-04
Recruiting
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
NCT06133972Systemic Lupus Erythematosus
Novartis Pharmaceuticals
Phase 3
550
Guangzhou, Shantou, Nanjing, Suzhou, Nanchang, Pingxiang, Changchun, Linyi
2024-05-21
Recruiting
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
NCT05939414Oligometastatic Prostate Cancer (OMPC)
Novartis Pharmaceuticals
Phase 3
450
Beijing, Guangzhou, Shanghai
2024-03-12
Recruiting
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
NCT05827081Early Breast Cancer
Novartis Pharmaceuticals
Phase 3
1,400
Beijing, Guangzhou, Harbin, Zhengzhou, Nanjing, Nanchang, Changchun, Jinan
2024-02-28
Active, closed
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
NCT05976243Chronic Inducible Urticaria
Novartis Pharmaceuticals
Phase 3
362
Fuzhou, Guangzhou, Changsha, Wuxi, Changchun, Jinan, Chengdu, Ürümqi
2023-12-07
Active, closed
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
NCT05985915Sjogrens Syndrome
Novartis Pharmaceuticals
Phase 3
612
Hefei, Chongqing, Guangzhou, Shenzhen, Wuhan, Baotou, Nanjing, Nanchang
2023-10-27
Active, closed
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
NCT05677451Chronic Spontaneous Urticaria
Novartis Pharmaceuticals
Phase 3
100
Guangzhou, Chengdu, Beijing
2023-07-11
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
Novartis Pharmaceuticals
Phase 3
383
Hefei, Beijing, Foshan, Guangzhou, Shenzhen, Nanning, Guiyang, Wuhan
2023-07-06
Active, closed
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
NCT05838768MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
Novartis Pharmaceuticals
Phase 1
123
Beijing, Guangzhou
2023-06-27
Active, closed
A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
NCT05658003Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals
Phase 2
63
Wuhan, Nanjing, Shenyang, Xian, Chengdu, Hangzhou, Beijing, Guangzhou
2023-05-05
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals
Phase 3
14,012
Guangzhou, Nanning, Cangzhou, Shijiazhuang, Tangshan, Xingtai, Daqing, Harbin
2023-03-09
Active, closed
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
NCT05639114Systemic Lupus Erythematosus
Novartis Pharmaceuticals
Phase 3
436
Guangzhou, Shantou, Haikou, Zhuzhou, Nanjing, Suzhou, Nanchang, Pingxiang
2023-03-02
Active, closed
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
NCT05653349Primary Immune Thrombocytopenia (ITP)
Novartis Pharmaceuticals
Phase 3
226
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Luoyang, Zhengzhou, Changzhou, Nanchang
2023-02-03
Active, closed
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
NCT05653219Primary Immune Thrombocytopenia
Novartis Pharmaceuticals
Phase 3
152
Guangzhou, Wuhan, Binzhou, Hangzhou, Beijing, Jinan, Tianjin
2023-02-02
Active, closed
A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia
NCT05648968Warm Autoimmune Hemolytic Anemia (wAIHA)
Novartis Pharmaceuticals
Phase 3
90
Guangzhou, Hangzhou, Dalian, Tianjin
2022-12-30
Active, closed
Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials
NCT05335876Spinal Muscular Atrophy (SMA)
Novartis Pharmaceuticals
Phase 3
20
Chongqing, Guangzhou, Chengdu, Beijing
2022-12-19
Active, closed
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
NCT05513001Chronic Spontaneous Urticaria
Novartis Pharmaceuticals
Phase 3
696
Guangzhou, Wuhan, Wuxi, Changchun, Chengdu, Hangzhou, Beijing, Shanghai
2022-12-09
Active, closed
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
NCT05544929Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial
Novartis Pharmaceuticals
Phase 1
126
Guangzhou, Beijing
2022-10-26
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Novartis Pharmaceuticals
Phase 4
347
Chongqing, Guangzhou, Zhengzhou, Wuhan, Changchun, Xian, Chengdu, Beijing
2022-08-30
Active, closed
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
NCT05126277Lupus Nephritis
Novartis Pharmaceuticals
Phase 3
452
Guangzhou, Shantou, Shenzhen, Liuzhou, Haikou, Wuhan, Changsha, Nanjing
2022-07-14
Active, closed
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer
NCT05132075Non-Small Cell Lung Cancer
Novartis Pharmaceuticals
Phase 3
95
Fuzhou, Guangzhou, Harbin, Changsha, Shengyang, Jinan, Hangzhou, Beijing
2022-06-15
Active, closed
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)
NCT05147220Relapsing Multiple Sclerosis
Novartis Pharmaceuticals
Phase 3
1,000
Guangzhou, Zhengzhou, Changsha, Baotou, Hohhot, Nanchang, Changchun, Beijing
2021-12-16
Active, closed
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
NCT05030428Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals
Phase 3
17,004
Beijing, Foshan, Guangzhou, Nanning, Harbin, Jingzhou, Wuhan, Changsha
2021-11-23
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Novartis Pharmaceuticals
Phase 3
405
Guangzhou, Shenzhen, Zhengzhou, Wuhan, Nanjing, Suzhou, Xian, Chengdu
2021-10-06
Active, closed
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
NCT04557462Primary IgA Nephropathy
Novartis Pharmaceuticals
Phase 3
448
Beijing, Guangzhou, Luoyang, Zhengzhou, Changsha, Changchun, Yinchuan, Taiyuan
2021-09-20
Recruiting
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
NCT04817618C3G
Novartis Pharmaceuticals
Phase 3
98
Guangzhou, Wuhan, Beijing, Shanghai
2021-07-28
Active, closed
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
NCT04720157Prostatic Neoplasms
Novartis Pharmaceuticals
Phase 3
1,140
Nanjing, Xian, Chengdu, Beijing, Guangzhou, Shanghai, Tianjin
2021-06-09
Active, closed
Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)
NCT04765657Hypercholesterolemia
Novartis Pharmaceuticals
Phase 3
345
Lanzhou, Foshan, Guangzhou, Shijiazhuang, Baotou, Hohhot, Nanjing, Nantong
2021-03-01
Active, closed
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT04699188KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
Novartis Pharmaceuticals
Phase 1/2
344
Guangzhou, Beijing
2021-02-24
Active, closed
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
NCT04544189Breast Neoplasms
Novartis Pharmaceuticals
Phase 2
69
Hefei, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Changsha, Nanjing
2021-01-20
Recruiting
Secukinumab Open Label Roll-over Extension Protocol
NCT04638647Autoimmunity, Inflammation
Novartis Pharmaceuticals
Phase 4
1,000
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Shantou, Shenzhen, Wuhan
2020-12-22
Active, closed
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments
NCT04058756Advanced Solid Tumors
Novartis Pharmaceuticals
Phase 1
120
Guangzhou
2019-10-30
Active, closed
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer
NCT03701334Early Breast Cancer
Novartis Pharmaceuticals
Phase 3
5,101
Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Nanjing, Suzhou, Changchun
2018-12-07
Active, closed
Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
NCT02584933ALK Positive Malignancies
Novartis Pharmaceuticals
Phase 4
233
Guangzhou, Changchun, Beijing
2015-12-11
Rows per page Showing 1–54 of 54
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.